Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$5.48 USD
-0.02 (-0.36%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $5.49 +0.01 (0.18%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRVS 5.48 -0.02(-0.36%)
Will CRVS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRVS
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
CRVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
Other News for CRVS
Biotech Alert: Searches spiking for these stocks today
Casella Waste Systems, SES AI And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday
Corvus Pharmaceuticals price target raised by $9 at Ladenburg, here's why
Biotech Alert: Searches spiking for these stocks today